Solid Tumor Market Size, Share, Growth, Trends, and Global Industry Analysis: By Tumor Type (Benign Tumor and Malignant Tumor), By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, Tyrosine Kinase Inhibitors, Proteasome Inhibitor, Hedgehog Pathway Inhibitor, and Others), By Drug Class (Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Proteasome Inhibitors, Monoclonal Antibodies, and Others), By Route of Administration (Oral, Parenteral, and Others) By End Users (Hospitals, Specialty Clinics, Homecare, and Others), and Region Forecast 2020-2031

Solid Tumor Market size was valued at US$ 4,832.3 million in 2024 and is projected to reach US$ 5,589.0 million by 2031 at a CAGR of 2.1% from 2025-2031. Moreover, the U.S. Solid Tumor Market is projected to grow significantly, reaching an estimated value of US$ 1,743.8 Million by 2031. The market focuses on the diagnosis, treatment, and management of solid tumors, which are abnormal masses of tissue that do not contain liquid or cyst areas.

The market is being primarily driven by the rising global cancer burden, particularly in high-incidence cancers like breast, lung, colorectal, and prostate. Aging populations, lifestyle risk factors, and improved diagnostic access have led to a growing patient pool, prompting increased investments in early detection, targeted therapies, and precision oncology. A major trend shaping the market is the integration of advanced diagnostics, especially liquid biopsies and AI-powered tools, which enable early detection, real-time monitoring, and personalized treatment decisions. These innovations are redefining clinical workflows and accelerating the shift toward data-driven, individualized care.

Expansion of immuno-oncology into early-stage cancers and new tumor types, supported by growing approvals for checkpoint inhibitors, ADCs, and tumor-agnostic drugs provides opportunity for the market. Additionally, biosimilars, mRNA cancer vaccines, and digital therapeutics are creating new growth avenues. However, high treatment costs remain a major restraint, limiting access, especially in low- and middle-income countries. Even in developed markets, cost-effectiveness concerns impact reimbursement and adoption. Other challenges include limited biomarker infrastructure and disparities in oncology workforce distribution. Despite these barriers, the market’s trajectory remains positive, propelled by innovation, policy support, and the urgent need for effective cancer solutions.

Facts & Figures

• Rising Global Prevalence of Cancer: The increasing prevalence of solid tumors, such as breast, lung, colorectal, and prostate cancers, is the primary demand driver. Aging populations, sedentary lifestyles, and environmental exposure continue to fuel cancer rates worldwide. For instance, according to GLOBOCAN 2024, global cancer cases are expected to reach over 30 million annually by 2040, up from 20 million in 2020, reinforcing sustained market demand for diagnostics and therapeutics.
• Technological Advancements in Diagnostics (Liquid Biopsies & AI): Advanced diagnostics like ctDNA-based liquid biopsies and AI-enabled imaging are transforming early detection, treatment planning, and recurrence monitoring for solid tumors. For instance, in June 2025, Guardant Health partnered with Pfizer to integrate its Infinity ctDNA platform into global trials, showing strong pharma confidence in non-invasive, precision-based diagnostics.
• Expansion of Immuno-Oncology into Early-Stage Settings: Checkpoint inhibitors and immunotherapies, once reserved for metastatic settings, are increasingly being approved for adjuvant and neoadjuvant use, expanding the addressable patient pool. For instance, at ASCO 2025, early-stage lung and bladder cancers showed strong response rates to PD-1/PD-L1 inhibitors. Approvals for earlier use of nivolumab and pembrolizumab now cover post-surgical and pre-operative settings, broadening commercial potential.
• Growing Focus on Emerging Markets and Biosimilars: With cancer care expanding in Asia, Latin America, and Africa, biosimilars of high-cost biologics are creating more affordable access to oncology treatments, especially in resource-limited settings. For instance, recently, Zydus Lifesciences partnered with Agenus to co-develop and commercialize biosimilar-grade immune checkpoint antibodies in India and the U.S., boosting scale and affordability in key geographies.

Key Developments

• In June 2025, BioNTech & Bristol Myers Squibb partnered on BNT327. A landmark co-development and co-commercialization agreement worth $11.1?billion focuses on a next-gen bispecific antibody for multiple solid tumors.
• In June 2025, BioNTech acquired CureVac for $1.25?billion. This all?stock merger strengthens BioNTech’s mRNA-based oncology pipeline beyond vaccines.
• In June 2025, QIAGEN & Tracer Biotechnologies form an MRD partnership
  They collaborated to develop blood-based MRD tests for solid tumors on QIAcuity, underscoring diagnostic innovation.
• In March 2025, AstraZeneca acquired EsoBiotec for up to $1?billion. Strengthening its in vivo CAR?T cell therapy capabilities for simpler cancer treatments.

Solid Tumor Market Segmentation

Based on the tumor type

• Benign Tumor
• Malignant Tumor

Based on tumor type, the malignant tumor segment holds the largest market share in the market. This is primarily due to the high prevalence of cancers such as breast, lung, colorectal, and prostate, which are classified as malignant and often require extensive treatment involving surgery, chemotherapy, radiotherapy, and targeted therapies. The rising global cancer burden, along with advancements in diagnostics and oncology drugs, further drives the dominance of this segment. On the other hand, benign tumors, though common, typically do not pose immediate life-threatening risks and require less aggressive treatment, resulting in a comparatively smaller market share.

Based on the therapy type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Tyrosine kinase inhibitors
• Proteasome inhibitor
• Hedgehog pathway inhibitor
• Others

Based on therapy type, targeted therapy holds the largest market share in the market due to its high efficacy, reduced side effects, and growing use across major cancers like breast, lung, and colorectal. Targeted therapies, including monoclonal antibodies and small molecules, are designed to interfere with specific molecular targets driving tumor growth, making them essential in precision oncology. Drugs like trastuzumab (HER2+ breast cancer) and osimertinib (EGFR-mutated NSCLC) have become standard-of-care treatments. Hedgehog pathway inhibitors represent the smallest market segment, largely due to their limited indications (e.g., basal cell carcinoma) and narrow patient base.

Based on the drug class

• Alkylating Agents
• Antimetabolites
• Topoisomerase Inhibitors
• Proteasome Inhibitors
• Monoclonal Antibodies
• Others

Based on drug class, monoclonal antibodies hold the largest market share in the market due to their targeted mechanism of action, proven clinical efficacy, and broad application across multiple high-incidence cancers such as breast, lung, and colorectal. These biologics offer greater specificity and fewer off-target effects compared to traditional chemotherapeutic agents, making them a preferred choice in modern oncology. Blockbuster drugs like trastuzumab (Herceptin), bevacizumab (Avastin), and pembrolizumab (Keytruda) have set the benchmark for monoclonal antibody success in solid tumors. In contrast, proteasome inhibitors, primarily used in hematologic malignancies, hold the smallest share in the solid tumor segment due to their limited approval and modest results in solid tumor indications.

Based on the route of administration

• Oral
• Parenteral
• Others

Based on the route of administration, parenteral administration holds the largest market share in the global solid tumor market. Most monoclonal antibodies, chemotherapies, and immunotherapies are administered intravenously or subcutaneously in clinical settings to ensure precise dosing, rapid action, and controlled bioavailability, especially for aggressive or advanced-stage cancers. Hospital infrastructure and infusion centers are well-equipped for parenteral regimens, which are preferred in both first-line and combination therapies. However, the oral segment is steadily growing due to patient preference for convenience and better compliance, particularly with targeted therapies and tyrosine kinase inhibitors, though it still accounts for a smaller overall share.

Based on the end users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Based on end users, hospitals hold the largest market share in the global solid tumor market due to their comprehensive oncology infrastructure, availability of multidisciplinary care, and ability to administer complex treatments such as parenteral chemotherapy, immunotherapy, and advanced diagnostics. Hospitals are the primary setting for cancer diagnosis, surgery, infusion therapies, and clinical trials, making them central to solid tumor management. They also serve as referral centers for severe and late-stage cases requiring intensive care. While specialty clinics are expanding in urban areas with outpatient services and targeted therapies, and home care is gaining traction for oral medications and palliative care, these segments still hold a smaller share compared to hospital-based oncology care.